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ABSTRACT
Objectives: Due to hormonal changes during the menopause, women experience a variety of perimenopause and post-
menopause symptoms. This review examines the various aspects of nanostructured hormone therapy and its application 
in the treatments of menopausal symptoms.
Material and methods: Excerpta Medica DataBase, Medical Literature Analysis and Retrieval System Online, Web of Science, 
and Google Scholar were searched basing on the Preferred Reporting Items for Systematic Reviews and Meta-Analyses 
guidelines. Seven eligible studies out of 51 related papers, which satisfied the initial search criteria, were extracted and 
carefully reviewed to clarify the role of nanomedicine in maintaining postmenopausal women’s health.
Results: Review of the seven eligible studies confirmed nanostructured hormone therapy as a safe and effective method 
for the alleviation of menopausal symptoms. According to the existing studies, nanostructured hormone therapy decreased 
the mean daily frequency and severity of menopausal symptoms.
Conclusion: The use of transdermal nanoformulations in hormone therapy can relieve climacteric symptoms and prevent 
other postmenopausal symptoms.
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INTRODUCTION
Menopause is an evolutionary process and a significant 
stage in any woman’s life [1, 2]. Changes during this stage 
increase the risk of diseases in women and make menopause 
the second cause of disability-adjusted life years (after cardio-
vascular diseases) in 45–60 year old women [1, 3]. Although 
recent medical advances and the consequent rise in life ex-
pectancy (from 40 to 84 years) have increased the number of 
postmenopausal women throughout the world [4], the age of 
menopause has remained almost constant, i.e. postmenopau-
sal years still constitute about one-third of women’s lives [5]. 
Therefore, menopause is a major health issue which manage-
ment will improve women’s quality of life and health status [6].
Hormones play a key role in human health and regula-
tion of vital processes. Due to hormonal changes during the 
menopause, women experience a variety of menopausal 
symptoms [1] including hot flushes, night sweats, sleep 
disorders, anxiety, irritability, and mood swings [7]. The man-
agement of such vasomotor symptoms, affecting the qual-
ity of life in 60–80% of postmenopausal women, requires 
hormone replacement therapy (HRT) [5]. However, a small 
proportion of women who experience these symptoms 
tend to seek medical treatment [8]. While the application 
of estrogen alone or in combination with progesterone 
(combined HRT) has long been considered as the treat-
ment of choice for menopausal symptoms [9], the results of 
Women’s Health Initiative (WHI) highlighted the health risks 
associated with HRT and indicated the need for alternative 
therapies [10]. Despite the widespread use of HRT in the 
alleviation of menopause symptoms, limited knowledge is 
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available about the efficacy of transdermal HRT (THRT) as 
an alternative to HRT in women who, for any reason, cannot 
use other routes of drug administration [11].
Nanomedicine, i.e. the application of nanoscience in 
various healthcare fields including the prevention, diag-
nosis, and treatment of diseases, has attracted increasing 
attention in today’s world [12]. Nanoparticles are between 
1 and 200 nanometers in size and have either chemical or 
biological origin [13]. In nanomedicine research, specific 
nanoparticles are designed for drug delivery. These carri-
ers improve the biodistribution of drugs by delivering ac-
tive molecules to target tissues while protecting adjacent 
healthy tissues [14]. Controlled release, targeted delivery, 
increased drug solubility and absorption, fewer side effects, 
lower frequency of drug administration and the consequent 
reduction in drug toxicity, and longer duration of drug ac-
tion are among the numerous advantages of nanomedi-
cines. Nanotechnology has in fact opened up new horizons 
in effective drug targeting through drug carrier systems [15].
Dermal delivery is one of the most important drug de-
livery routes in novel pharmaceutics. In transdermal drug 
delivery, the drug moves along different layers of the skin 
and creates the desired response by entering the systemic 
circulation [16]. Nanocarriers can either remain unchanged 
after penetration into the skin or break down and release 
the active components into various layers of the skin [17]. 
Transdermal drug delivery has several benefits: it maintains 
constant plasma levels of the drug for longer periods of 
time (compared to oral administration), eliminates first-pass 
metabolism and drug destruction by digestive agents, and 
increases patient compliance [18].
The development of nanotechnology can potentially fa-
cilitate health promotion among older adults [19]. As a result 
of increasing attention to nanotechnology in dealing with 
health challenges faced by the older population [20], great 
advances have been made in the design of nanoformulation 
for various conditions including breast cancer, hearing loss, 
and cardiovascular and central nervous system diseases [19]. 
New evidence has also suggested the unique properties of 
nanostructured HRT in the management of climacterium 
symptoms [21]. However, since the exact benefits of such 
protocols are still under debate, the present study reviewed 
different aspects of nanostructured HRT and its applications 
in alleviating menopausal symptoms. 
MATERIAL AND METHODS
Literature search strategy
The guidelines of Preferred Reporting Items for Systemat-
ic Reviews and Meta-Analyses (PRISMA) and Cochrane Hand-
book for Systematic Reviews of Interventions were adopted 
to search Medical Literature Analysis and Retrieval System 
Online (MEDLINE), Cochrane, Excerpta Medica DataBase 
(EMBASE), Web of Science, and Google Scholar databases 
for papers published until February, 2016. A number of key 
terms including menopausal symptoms, perimenopause, 
postmenopause, climacteric, hormone therapy nanostruc-
tured medicine were used in all searchers. The keywords in 
each group were combined using the Boolean operator “OR”. 
All searches contained at least one keyword from each group 
combined using the Boolean operator “AND”. Papers in all 
languages would be surveyed if they reported placebo-con-
trolled clinical trials on the use of nanostructured transdermal 
HRT to relieve menopausal symptoms in perimenopausal or 
postmenopausal women. Studies with only one active control 
group and without quantitative outcome data were excluded.
Study selection and data extraction 
Two independent reviewers (F.A. and T.D.) used the 
above-mentioned set of inclusion and exclusion criteria for 
the preliminary extraction of the studies. Cases of disagree-
ment about the eligibility of studies were resolved by con-
sulting a third reviewer. The first author’s name, year of pub-
lication, study type and design, number of participants, and 
evaluated outcomes were extracted from all eligible papers.
Quality Appraisal
The systematic review was reported following the 
PRISMA checklist. Methodological elements including data 
collection, accurate description of sampling, study setting, 
characteristics of participants and inclusion and exclusion 
criteria were evaluated to ensure the quality of the selected 
papers. All eligible studies were carefully reviewed. The qual-
ity of trials was assessed using the Cochrane Collaboration’s 
tool for assessing the risk of bias in randomized trials. 
RESULTS
A total of 119 related papers were identified, 51 of which, 
satisfied the search criteria, but only 15 papers containing 
the application of nanotechnology in the management of 
menopausal symptoms were potentially retrievable. Ulti-
mately, seven eligible studies were included and thoroughly 
reviewed. Figure 1 presents a flow diagram of the study 
selection procedure.
Most studies confirmed nanostructured HRT as a safe and 
effective method of restoring normal estradiol serum levels 
and alleviating menopausal symptoms. The application of 
transdermal nanoformulations for HRT was also found to 
relieve the climacteric syndrome and prevent several meno-
pausal symptoms. A main variable measured by the majority 
of researchers was the mean daily reduction in the frequency 
of menopausal symptoms during the course of the treat-
ment. Although limited knowledge about the efficacy of 
nanomedicines in decreasing menopausal symptoms is avail-
able, the reviewed studies suggested the positive effects of 
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nanostructured HRT on menopausal symptoms and clinical 
parameters. Another advantage of such nanomedicines was 
their fewer side effects compared to conventional medicines 
used in HRT. Table 1 summarizes the reviewed papers.
Table 1. Reviewed papers about the application of nanostructured HRT in the treatment of menopausal symptoms
1st author,  
year of publication Research information
Simon, 2006 
[22]
Title: Estradiol in micellar nanoparticles: the efficacy and safety of a novel transdermal drug-delivery technology in the 
management of moderate to severe vasomotor symptoms
Type of study: Double-blind randomized placebo-controlled clinical trial
Participants: 200 postmenopausal women
Study design: A multi-center double-blind randomized placebo-controlled clinical trial with a three-week screening period 
followed by one week of treatment with a placebo emulsion and then 12 weeks of treatment with either placebo or a micellar 
nanoparticle estradiol emulsion (MNPEE). Women were randomly allocated to placebo and MNPEE groups (at a 1:1 ratio)
The MNPEE group received 3.45 g/day of an estradiol emulsion, i.e. 8.6 mg/day estradiol. The placebo group received similar 
amounts of a placebo emulsion. The primary efficacy variable was the reduction in the number of moderate-severe hot flushes 
per day at the fourth and 12th weeks. The adverse effects of treatments were also evaluated throughout the study
Outcomes: The treatment could effectively reduce the frequency of moderate-severe hot flushes per day from baseline to 
the 12th week (–11.1 ± 6.8 times per day after estradiol use and –7.2 ± 5.4 times per day after placebo use; p < 0.001). The 
efficacy of MNPEE in reducing the frequency of hot flushes was significantly higher than that of placebo at from weeks three 
to 12. At the 12th week, MNPEE could decrease the daily frequency of hot flushes by 11.1 times
Botelho, 2014 
[21]
Title: Nanostructured transdermal hormone replacement therapy for relieving menopausal symptoms: a confocal 
Raman spectroscopy study
Type of study: Long-term clinical trial
Participants: 66 postmenopausal women with climacteric syndrome
Study design: In order to provide a hormone secretion pattern similar to that of normal ovaries, the participants were 
asked to apply transdermal nanostructured progesterone and estrogen formulations on their forearms every day for 
60 months. The assessment of hormones in different skin layers was conducted using confocal Raman spectroscopy. The 
participants’ blood pressure, serum levels of estradiol and follicle-stimulating hormone (FSH), clinical parameters, bilateral 
mammographic findings, and severity of symptoms were evaluated during the 60-month period of the study
Outcomes: After 60 months of treatment, 92.5% of the participants reported reductions in the severity of climacteric 
symptoms. Significant changes in serum levels of estradiol and FSH were observed after treatment. Serum FSH levels 
decreased from 82.04 ± 4.9 IU/mL at baseline to 57.12 ± 4.1 IU/mL after 60 months. The results of bilateral mammography 
were normal in all women. No particular adverse health events were detected during the treatment course
Figure 1. The algorithm of study selection for the systematic review
PubMed
n = 29
Science Direct
n = 14
Scopus
n = 21
Proquest
n = 8
Records identied through database 
searching or through sources 
(n = 119)
Cochrane
n = 6
Google Scholar
n = 25
Web of Science
n = 16
Records after the removal 
of duplicates 
(n = 82)
Studies eliminated due 
to lack of relevance
(n = 36)
Full-text articles excluded, 
with reasons 
(n = 15)
Records screened 
(n = 51)
Articles included
(n = 7)
→
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Table 1 (cont.). Reviewed papers about the application of nanostructured HRT in the treatment of menopausal symptoms
1st author,  
year of publication Research information
Boxenbaum, 2002 
[23]
Title: Pharmacokinetics of Estrasorb, a topical lotion for treatment of postmenopausal vasomotor symptoms
Type of study: Phase I clinical trial
Participants: Eight postmenopausal women
Study design: The first phase of the study was conducted on a group of postmenopausal women and pharmacokinetics of 
a micellar nanoparticle estradiol emulsion (MNPEE) containing 7.5 mg estradiol was evaluated once daily
Outcomes: The daily frequency of moderate-severe hot flushes was reduced following the treatment. Since the final half-
life of estradiol was about 2.4 days (with a cumulative index of four), MNPEE had a stable drug release. The daily systemic 
dose of estradiol delivered was estimated at 0.05 mg
Gonzaga, 2012
[11]
Title: Nanotechnology in hormone replacement therapy: Safety and efficacy of transdermal estriol and estradiol 
nanoparticles after 5 years of follow-up
Type of study: Clinical trial
Participants: 122 postmenopausal women with natural menopause
Study design: The participants received a transdermal formulation of estriol (0.1%) + estradiol (0.25%) on their right 
forearm for five years. The aim was to restore serum levels of hormones and to alleviate menopausal symptoms. The 
reduction in symptoms (based on self-report), serum estradiol levels, weight, blood pressure, and bilateral mammography 
findings were measured at baseline and after 60 months of treatment
Outcomes: The transdermal estradiol nanoformulation enhanced the measured clinical parameters. Patients’ satisfaction 
was calculated as 92%. While serum estradiol levels changed significantly after treatment, no significant differences in 
weight and systolic and diastolic blood pressure were observed during the course of the study
Simon, 2007 
[24]
Title: Estradiol topical emulsion (ETE) for the treatment of moderate-to-severe vasomotor symptoms associated with 
menopause
Type of study: Phase II placebo-controlled clinical trial
Participants: 125 postmenopausal women with moderate to severe hot flushes
Study design: The efficacy and safety of three doses of ETE (1.15, 2.30, or 3.45 g of emulsion containing 2.5 mg/g estradiol) 
was evaluated in 125 postmenopausal women. The treatment course lasted for 28 days. The frequency and severity of hot 
flushes were measured during a one-week treatment with placebo and the 28-day treatment with ETE
Outcomes: After 4 weeks of treatment with the confirmed dosage of ETE, 45% of women reported complete relief of 
moderate to severe hot flushes. This rate was 9% in the placebo group. Maximum reduction in hot flushes occurred after 
12 weeks of receiving ETE (–11.1 ± 6.8 hot flushes per day in the ETE group vs. –7.2 ± 5.4 hot flushes per day in the placebo 
group; p < 0.001)
Taylor, 2008 
[25]
Title: Absorption, bioavailability, and partner transfer of estradiol from a topical emulsion 
Type of study: Open-label, non-randomized clinical trial
Participants: 14 postmenopausal women and their male partners
Study design: Women were asked to apply 1.74 g/day of a topical estradiol emulsion (containing 2.5 mg/g estradiol) to 
each leg on two consecutive days. In order to expose their partners, women were also asked to maintain close skin-to-skin 
contact with their male partners two and eight hours after the application of the emulsion
Outcomes: Serum levels of estradiol, estrone, and estrone sulfate were evaluated in both female and male subjects. The 
mean estradiol levels in women were 2.9 ± 1.5, 15.3 ± 14.8, and 27.6 ± 22.7 pg/mL at baseline, the first day of treatment, and 
the second day, respectively. Their geometric mean fold ratio for the area under the serum level-time curve from 0–24 hours 
was 1.25. Close skin-to-skin contact with women at application sites transferred estradiol to their male partners. While 
estradiol levels in men significantly increased after exposure, all levels remained in the normal range
Botelho, 2015 
[26]
Title: Effects of a transdermal testosterone metered-dose nanoemulsion in peri- and postmenopausal women: a novel 
protocol for treating low libido
Type of study: Clinical trial
Participants: 24 women (mean age: 51.7 years) with decreased libido
Study design: Women were asked to apply a novel transdermal formulation containing 500 µg/day testosterone on 
their right arm. The treatment continued for 12 weeks. Breast examination and blood tests were performed four weeks 
before treatment. A questionnaire was administered to assess women’s complaints about decreased libido before and 
after treatment. Clinical and laboratory parameters including decreased libido, serum testosterone, insulin, and C-reactive 
protein levels, weight, blood pressure, body mass index (BMI), and waist circumference were measured
Outcomes: The mean serum testosterone levels significantly increased after 12 weeks of treatments. No adverse 
androgenic effects or significant changes in the participants’ weight were observed during the course of treatment. 
However, the clinical parameters significantly improved after treatment. While only 38% of the participants were satisfied 
with their sexual function before treatment, this rate increased to 82% after treatment
DISCUSSION
The findings of the present review highlighted the po-
tential benefits of nanostructured medicines in alleviating 
peri- and postmenopause symptoms. Although the existing 
epidemiological data suggest the efficacy of nanomedicines 
in the management of menopausal symptoms in women 
of many nations, further research is warranted to confirm 
such effects.
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Nanotechnology is a novel field of science. Nanostruc-
tured medicines have shown unique and remarkable prop-
erties such as skin absorption. Controlled release of drugs 
is another fascinating property of nanomedicines which 
may play a major role in public health and promotion in 
the future [11]. A variety of techniques, including the use 
of nanomedicines, have been applied in transdermal drug 
delivery to increase the penetration of therapeutic mol-
ecules into the skin [17]. Due to their high loading capac-
ity, long release time, and high transdermal penetration 
caused by their mechanical flexion (which enables them 
to reach even lymph nodes), nanoparticles based on poly-
mers and polysaccharides, as well as nanostructured lipid 
carriers (NLCs) and solid lipid nanoparticles (SLNs), have 
received increasing attention during the recent years [27]. 
Nanomedicines are drug carriers specifically designed to 
deliver active molecules to the target tissues while protect-
ing healthy tissues. Such a process is believed to enhance 
the biodistribution of drugs [14]. Accurate drug targeting 
will minimize not only the required dose for effective treat-
ment, but also the possible drug side effects [28]. De Vargas 
et al. designed a procedure to develop topical hydrogels 
containing genistein-loaded nanoemulsions. The result was 
monodisperse nanoemulsions (in the 250 nm range) with 
low viscosity and negative zeta potential. The application of 
these nanoemulsions caused a slow flow of genistein into 
the skin. Therefore, the researchers recommended hydrogels 
containing loaded nanoemulsions as effective formulations 
for transdermal delivery of isoflavones [29].
According to the current review, researchers around 
the world are interested in the use of nanotechnology for 
the management of menopausal symptoms. Botelho et al. 
reported the use of nanoparticles in transdermal HRT as 
a safe and efficient controlled drug release system to allevi-
ate menopausal symptoms [21]. In another study, Botelho 
et al. evaluated the efficacy of a novel transdermal delivery 
system using a nanostructured formulation containing tes-
tosterone and progesterone. They found the treatment to 
improved satisfaction with sexual performance from 38% to 
82% and concluded that increasing testosterone levels could 
effectively resolve climacteric symptoms in postmenopausal 
women with decreased libido [26]. Gonzaga et al. examined 
the safety and efficacy of a new protocol for the application 
of transdermal estriol and estradiol nanoparticles in HRT. Their 
findings indicted the efficacy of the developed transdermal 
drug delivery system. The treatment improved clinical pa-
rameters but had no significant effects on women’s weight 
or blood pressure. The rate of satisfaction with treatment was 
92% [11]. Taylor et al. found that close skin-to-skin contact 
with postmenopausal women who applied a topical estradiol 
emulsion resulted in the transfer of estradiol from women to 
their partners. Although this exposure significantly increased 
estradiol levels in men, the levels of this hormone remained 
in the normal range [25]. Estrasorb® is an estradiol topical 
emulsion which uses micellar nanoparticles for drug delivery. 
When applied on the skin, micellar nanoparticles accumulate 
on the outer layer of the skin and the estradiol emulsion 
gradually penetrates into the skin and reaches blood circu-
lation. Estrasorb® contains 2.5 mg/g estradiol hemihydrate 
and its pharmacokinetic profile suggests minimal changes in 
serum levels of estradiol [30]. Transdermal hormone delivery 
systems (THDSs) consist of a backing layer and an adjoining 
adhesive polymer matrix. In order for a THDS to be effec-
tive, the matrix should contain a minimal amount of the 
hormone which delivery is improved by one or more skin 
permeation-enhancing agents. With a THDS, effective daily 
doses of progesterone and estrogen can be delivered through 
a small area of the skin [31].
In a multicenter trial, Simon suggested micellar nano-
particle estradiol emulsion (MNPEE) as an effective, safe, and 
well-tolerated technology for reducing the frequency and se-
verity of moderate to severe vasomotor symptoms [22]. Drug 
carriers enhance the physicochemical properties of drugs, 
facilitate the penetration of drug molecules into the skin, and 
improve skin permeation by skin hydration and interaction 
with skin lipids [32]. Case-control studies have shown a lower 
risk of venous thromboembolism (VTE) with transdermal es-
trogen therapy than with the oral administration of estrogen 
[33]. This finding was confirmed by a cohort study in which 
transdermal estrogens and the risk of VTE recurrence were 
not correlated [34]. A case-control study compared the risk 
of stroke following transdermal and oral HRT and concluded 
that transdermal HRT did not increase the risk of stroke [35].
In their attempts to provide insight into the application 
and effects of nanomedicine on common age-related health 
issues, recent studies have described the fundamental con-
cepts and clinical applications of this modern science in 
promoting elderly health. Apparently, the development 
of nanotechnology can potentially lead to genomic and 
proteomic discoveries which improve elderly health [19]. 
CONCLUSIONS
In conclusion, nanostructured medicines can play a role 
in a cure of menopausal symptoms by ensuring that a suf-
ficient amount of the drug enters the body. Nevertheless, the 
amount of drug loading along with control of drug release 
and drug penetration into blood circulation are still major 
challenges in the application of transdermal drug delivery to 
manage premenopause and postmenopause symptoms. Fur-
ther studies are hence required to clarify the efficacy of na-
noparticles in alleviating menopausal symptoms. We hope 
that this paper has illuminated the remarkable and extensive 
implications of nanotechnology in enhancing the life expec-
tancy, health, and independence of older adults.
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Strengths and limitations of this study
• This review examines the various aspects of nanostruc-
tured hormone therapy and its application in the treat-
ments of climacterium symptoms.
• Systematic reviews will provide the highest level of 
evidence for informed decisions. To the best of our 
knowledge, no systematic review has been conducted 
on this topic.
• Two independent authors will screen and extract the 
records.
• One limitation of this study is the lack of studies in nano-
technology approaches in the management of peri- and 
postmenopausal symptoms. 
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